Vol. 23/No. 6

Frontline treatments that achieve transfusion independence are of paramount importance for patients with lower-risk myelodysplastic syndrome.

Sara A. Hurvitz, MD, FACP, led a panel of breast cancer experts—Aditya Bardia, MD, MPH; Patrick Neven, MD, PhD; and Kevin Kalinsky, MD, MS—in a review of key data from the 2021 San Antonio Breast Cancer Symposium in ER-positive breast cancer.

Encouraging response rates to a dual-targeted regimen in patients with recurrent or refractory malignant brain tumors with BRAF V600E mutations were reported in 2021, representing a new potential targeted therapy strategy against glioblastoma.

Data presented at the ASH Annual Meeting and Exposition underscored the growing focus on improving screening, advancing methods of detection, and improving our understanding of the genomic, genetic, and epigenetic factors that govern progression and therapeutic resistance in multiple myeloma.

A panel of lung cancer experts from China, South Korea, and Japan share their insights on how they care for their patients with resectable EGFR-positive non–small cell lung cancer.

The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma, following 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Maurie Markman, MD, discusses the expansion and overlap of the language of science within different medical disciplines and the general public.

Safety profiles of anticancer drugs represent only one piece of the toxicity puzzle patients grapple with following a cancer diagnosis.